BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22467513)

  • 1. Conditional expression of Lodavin, an avidin-tagged LDL receptor, for biotin-mediated applications in vivo.
    Murugan S; Saarela U; Airenne K; Shan J; Skovorodkin I; Ylä-Herttuala S; Vainio SJ
    Genesis; 2012 Sep; 50(9):693-9. PubMed ID: 22467513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein.
    Lehtolainen P; Wirth T; Taskinen AK; Lehenkari P; Leppänen O; Lappalainen M; Pulkkanen K; Marttila A; Marjomäki V; Airenne KJ; Horton M; Kulomaa MS; Ylä-Herttuala S
    Gene Ther; 2003 Dec; 10(25):2090-7. PubMed ID: 14595382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avidin fusion protein-expressing lentiviral vector for targeted drug delivery.
    Lesch HP; Pikkarainen JT; Kaikkonen MU; Taavitsainen M; Samaranayake H; Lehtolainen-Dalkilic P; Vuorio T; Määttä AM; Wirth T; Airenne KJ; Ylä-Herttuala S
    Hum Gene Ther; 2009 Aug; 20(8):871-82. PubMed ID: 19419273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient gene therapy based targeting system for the treatment of inoperable tumors.
    Wirth T; Pikkarainen JT; Samaranayake HD; Lehtolainen-Dalkilic P; Lesch HP; Airenne KJ; Marjomäki V; Ylä-Herttuala SP
    J Gene Med; 2012 Apr; 14(4):221-30. PubMed ID: 22411578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of vaccinia virus using biotin-avidin viral coating and biotinylated antibodies.
    Purow B; Staveley-O'Carroll K
    J Surg Res; 2005 Jan; 123(1):49-54. PubMed ID: 15652950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avidin-biotin interaction mediated peptide assemblies as efficient gene delivery vectors for cancer therapy.
    Qu W; Chen WH; Kuang Y; Zeng X; Cheng SX; Zhou X; Zhuo RX; Zhang XZ
    Mol Pharm; 2013 Jan; 10(1):261-9. PubMed ID: 23146022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
    Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
    Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro targeting of avidin-expressing glioma cells with biotinylated persistent luminescence nanoparticles.
    Maldiney T; Kaikkonen MU; Seguin J; le Masne de Chermont Q; Bessodes M; Airenne KJ; Ylä-Herttuala S; Scherman D; Richard C
    Bioconjug Chem; 2012 Mar; 23(3):472-8. PubMed ID: 22250884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of drug targeting based on recombinant expression of the chicken avidin gene.
    Walker L; Kulomaa MS; Bebok Z; Parker WB; Allan P; Logan J; Huang Z; Reynolds RC; King S; Sorscher EJ
    J Drug Target; 1996; 4(1):41-9. PubMed ID: 8798877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avidin-biotin technology in targeted therapy.
    Lesch HP; Kaikkonen MU; Pikkarainen JT; Ylä-Herttuala S
    Expert Opin Drug Deliv; 2010 May; 7(5):551-64. PubMed ID: 20233034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery via avidin fusion protein: intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes.
    Soininen SK; Lehtolainen-Dalkilic P; Karppinen T; Puustinen T; Dragneva G; Kaikkonen MU; Jauhiainen M; Allart B; Selwood DL; Wirth T; Lesch HP; Määttä AM; Mönkkönen J; Ylä-Herttuala S; Ruponen M
    Eur J Pharm Sci; 2012 Dec; 47(5):848-56. PubMed ID: 22985874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery.
    Kaikkonen MU; Lesch HP; Pikkarainen J; Räty JK; Vuorio T; Huhtala T; Taavitsainen M; Laitinen T; Tuunanen P; Gröhn O; Närvänen A; Airenne KJ; Ylä-Herttuala S
    Gene Ther; 2009 Jul; 16(7):894-904. PubMed ID: 19440224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans.
    Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
    Bioconjug Chem; 2008 Mar; 19(3):731-9. PubMed ID: 18278853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping of the fate of cell lineages generated from cells that express the Wnt4 gene by time-lapse during kidney development.
    Shan J; Jokela T; Skovorodkin I; Vainio S
    Differentiation; 2010 Jan; 79(1):57-64. PubMed ID: 19740593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.
    Campos SK; Parrott MB; Barry MA
    Mol Ther; 2004 Jun; 9(6):942-54. PubMed ID: 15194061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced gene delivery by avidin-displaying baculovirus.
    Räty JK; Airenne KJ; Marttila AT; Marjomäki V; Hytönen VP; Lehtolainen P; Laitinen OH; Mähönen AJ; Kulomaa MS; Ylä-Herttuala S
    Mol Ther; 2004 Feb; 9(2):282-91. PubMed ID: 14759812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.
    Morizono K; Xie Y; Helguera G; Daniels TR; Lane TF; Penichet ML; Chen IS
    J Gene Med; 2009 Aug; 11(8):655-63. PubMed ID: 19455593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain.
    Penichet ML; Kang YS; Pardridge WM; Morrison SL; Shin SU
    J Immunol; 1999 Oct; 163(8):4421-6. PubMed ID: 10510383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switchavidin: reversible biotin-avidin-biotin bridges with high affinity and specificity.
    Taskinen B; Zauner D; Lehtonen SI; Koskinen M; Thomson C; Kähkönen N; Kukkurainen S; Määttä JA; Ihalainen TO; Kulomaa MS; Gruber HJ; Hytönen VP
    Bioconjug Chem; 2014 Dec; 25(12):2233-43. PubMed ID: 25405260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of NADPH-cytochrome P450 reductase antisense oligos using avidin-biotin approach.
    Pillai VC; Yesudas R; Shaik IH; Thekkumkara TJ; Bickel U; Srivenugopal KS; Mehvar R
    Bioconjug Chem; 2010 Feb; 21(2):203-7. PubMed ID: 20063878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.